Response to dengue fever - The good, the bad, and the ugly?

New England Journal of Medicine

Volumn 363, Issue 5, 2010, Pages 484-487

  Schmidt, Alexander C ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN RECEPTOR; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

AGE DISTRIBUTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CLINICAL FEATURE; DENGUE; HUMAN; IMMUNOGENICITY; PRIORITY JOURNAL; URBAN AREA; VIRUS NEUTRALIZATION;

EID: 77955065003     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcibr1005904     Document Type: Article

References (5)

1. Dejnirattisai W, Jumnainsong A, Onsirisakul N, et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science 2010;328:745-8.
2. Halstead SB. Dengue. Lancet 2007;370:1644-52.
3. Pierson TC, Fremont DH, Kuhn RJ, Diamond MS. Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Cell Host Microbe 2008;4:229-38.
4. Rodenhuis-Zybert IA, van der Schaar HM, da Silva Voorham JM, et al. Immature dengue virus: a veiled pathogen? PLoS Pathog 2010;6(1):e1000718.
5. Whitehead SS, Blaney JE, Durbin AP, Murphy BR. Prospects for a dengue virus vaccine. Nat Rev Microbiol 2007;5:518-28.